Similarly, future clinical studies for therapeutic angiogenesis using AGGF1 with a plasmid-based gene delivery system are needed to unequivocally establish the efficacy of AGGF1 treatment for PAD. This evidence concerns the gene AGGF1 and peripheral arterial disease.